About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Care & Law
Part 2: Risk Management Recommendations
A malpractice claims analysis by an insurer, Healthcare Providers Service Organization, provides recommendations for avoiding errors and injuries. Case examples relate these suggestions to situations that are common in health care settings.
James O’Donnell, PharmD; and F. Randy Vogenberg, RPh, PhD
More Regulatory Changes Are in the Offing in 2015
Provisions in the Patient Protection and Affordable Care Act aim to reduce hospital admissions — and, by extension, hospital revenue. In some cases, the emphasis on bundled payments and other initiatives is speeding consolidations and closures.
The influence of genetics on pharmacokinetics can introduce variability among individual patients that may cause treatment failure, toxicity, or both. Such variability, specifically in clearance rates, can influence drug maintenance dosing regimens.
Paul Westervelt; Kihoon Cho; David R. Bright, PharmD; and David F. Kisor, PharmD
Schizophrenia is a complex disorder characterized by an array of symptoms. This heterogeneity has resulted in a lack of consensus regarding diagnostic criteria, etiology, and pathophysiology, and has complicated efforts to devise effective treatments.
Krishna R. Patel, PharmD, RPh; Jessica Cherian, PharmD, RPh; Kunj Gohil, PharmD, RPh; and Dylan Atkinson
New medications may soon offer more effective treatments for the approximately 2.5 million patients globally with schizophrenia. Current therapies in 2012 yielded $5.2 billion in global market sales, but by 2022 that is expected to reach $7.9 billion.
Kunj Gohil, PharmD, RPh; and Brielle Carramusa
Matthew Grissinger, RPh, FaScP
FDA approvals, drug indications, and updates
Belinostat (Beleodaq) for peripheral T-cell lymphoma; C1-esterase inhibitor (Ruconest) for acute attacks in hereditary angioedema; and tedizolid phosphate (Sivextro) for acute bacterial skin and skin structure infections
Marvin M. Goldenberg, PhD, RPh, MS
A New and Innovative Formulation of an Antipsychotic Treatment for Agitation
Jose Valdes, PharmD; Travis Shipley; and Jose A. Rey, MS, PharmD, BCPP